

Patrick Veit-Haibach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6514453/publications.pdf>

Version: 2024-02-01

100
papers

2,185
citations

236912

25
h-index

265191

42
g-index

102
all docs

102
docs citations

102
times ranked

2936
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 240-248.	3.9	21
2	Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1012-1020.	6.4	9
3	The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1677-1684.	1.9	1
4	Survival prediction using radiomic signatures in metastatic gastric and esophageal adenocarcinoma (GEA).. <i>Journal of Clinical Oncology</i> , 2022, 40, 357-357.	1.6	0
5	Combined 18F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer. <i>Clinical Nuclear Medicine</i> , 2022, 47, 684-691.	1.3	14
6	Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2022, 304, 566-579.	7.3	33
7	Comparison of four clinical prognostic scores in patients with advanced gastric and esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4057-4057.	1.6	0
8	How to Design AI-Driven Clinical Trials in Nuclear Medicine. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 112-119.	4.6	17
9	EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1188-1199.	6.4	23
10	Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 199-207.	2.8	12
11	CT perfusion in peripheral arterial disease—hemodynamic differences before and after revascularisation. <i>European Radiology</i> , 2021, 31, 5507-5513.	4.5	11
12	Quantitative ⁶⁸ Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1406-1414.	5.0	40
13	Role of intravoxel incoherent motion parameters in gastroesophageal cancer: relationship with 18F-FDG-positron emission tomography, computed tomography perfusion and magnetic resonance perfusion imaging parameters. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 178-186.	0.7	0
14	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3702-3711.	6.4	15
15	Deep learning for whole-body medical image generation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3817-3826.	6.4	12
16	Predictors of survival after metastasectomy of oligometastatic recurrence following gastroesophageal cancer treatment.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16060-e16060.	1.6	0
17	Neuroendocrine Tumors. <i>PET Clinics</i> , 2021, 16, 353-364.	3.0	3
18	18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. <i>Current Oncology</i> , 2021, 28, 3251-3258.	2.2	2

#	ARTICLE	IF	CITATIONS
19	A Pre-TACE Radiomics Model to Predict HCC Progression and Recurrence in Liver Transplantation: A Pilot Study on a Novel Biomarker. <i>Transplantation</i> , 2021, 105, 2435-2444.	1.0	20
20	The association between lesion tracer uptake on ⁶⁸ Ga-DOTATATE PET with morphological response to ¹⁷⁷ Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 73-77.	1.1	3
21	Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 24.	1.5	31
22	Evaluation of ¹⁸ F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 163-170.	2.0	7
23	Convolutional neural networks for improving image quality with noisy PET data. <i>EJNMMI Research</i> , 2020, 10, 105.	2.5	47
24	PET/Magnetic Resonance Imaging Applications in Abdomen and Pelvis. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2020, 28, 369-380.	1.1	9
25	Prognostic value of O-(2-[¹⁸ F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. <i>Acta Oncologica</i> , 2020, 59, 1357-1364.	1.8	0
26	Nuclear medicine and molecular imaging advances in the 21st century. <i>British Journal of Radiology</i> , 2020, 93, 20200095.	2.2	42
27	The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases: A simulation study combining multi-center data and ADNI-data. <i>PLoS ONE</i> , 2020, 15, e0233886.	2.5	6
28	¹⁸ F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1615-1620.	5.0	4
29	Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. <i>Radiotherapy and Oncology</i> , 2020, 150, 62-69.	0.6	3
30	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 15, 162-172.	0.6	12
31	Outcomes relative to paclitaxel dose-intensity when administered with ramucirumab in gastric and gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16539-e16539.	1.6	0
32	Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4557-4557.	1.6	0
33	Title is missing!. , 2020, 15, e0233886.		0
34	Title is missing!. , 2020, 15, e0233886.		0
35	Title is missing!. , 2020, 15, e0233886.		0
36	Title is missing!. , 2020, 15, e0233886.		0

#	ARTICLE	IF	CITATIONS
37	Driving the Future of Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1S-2S.	5.0	9
38	CT-perfusion in peripheral arterial disease – Correlation with angiographic and hemodynamic parameters. <i>PLoS ONE</i> , 2019, 14, e0223066.	2.5	14
39	Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR. <i>Medical Physics</i> , 2019, 46, 1677-1685.	3.0	22
40	Editorial commentary: Imaging the aorta for inflammation: Informing practice on emerging molecular techniques. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 449-450.	4.9	0
41	EJNMMI supplement: bringing AI and radiomics to nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2627-2629.	6.4	10
42	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2019, 191, 289-297.	1.3	15
43	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019, 58, 68-76.	0.7	20
44	¹⁸ F-FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: A meta-analysis of reported studies. <i>Head and Neck</i> , 2019, 41, 551-561.	2.0	24
45	Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer. <i>American Journal of Roentgenology</i> , 2019, 212, 377-381.	2.2	17
46	Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 171-171.	1.6	1
47	Radiomics in nuclear medicine and hybrid imaging: current standings on clinical applicability. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 321-322.	0.7	0
48	¹⁸ F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. <i>British Journal of Radiology</i> , 2018, 91, 20170814.	2.2	10
49	Influence of inter-observer delineation variability on radiomics stability in different tumor sites. <i>Acta Oncologica</i> , 2018, 57, 1070-1074.	1.8	152
50	Value of ¹⁸ F-FET PET in adult brainstem glioma. <i>Clinical Imaging</i> , 2018, 51, 68-75.	1.5	8
51	Pulmonary nodule detection in oncological patients – Value of respiratory-triggered, periodically rotated overlapping parallel T2-weighted imaging evaluated with PET/CT-MR. <i>European Journal of Radiology</i> , 2018, 98, 165-170.	2.6	13
52	Reduction of ¹⁸ F-FDG Dose in Clinical PET/MR Imaging by Using Silicon Photomultiplier Detectors. <i>Radiology</i> , 2018, 286, 249-259.	7.3	59
53	Impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous ¹⁸ F-choline PET/MRI for prostate cancer. <i>EJNMMI Research</i> , 2018, 8, 41.	2.5	12
54	Value of PET/MRI for assessing tumor resectability in NSCLC – intra-individual comparison with PET/CT. <i>British Journal of Radiology</i> , 2018, , 20180379.	2.2	8

#	ARTICLE	IF	CITATIONS
55	18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer, 2018, 18, 548.	2.6	25
56	Feasibility of ¹⁸ F-FDG Dose Reductions in Breast Cancer PET/MRI. Journal of Nuclear Medicine, 2018, 59, 1817-1822.	5.0	14
57	Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer. Anticancer Research, 2018, 38, 685-690.	1.1	29
58	Evaluation of multifunctional imaging parameters in gastro-oesophageal cancer using F-18-FDG-PET/CT with integrated perfusion CT. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, , .	0.7	1
59	Effect of Time-of-Flight Information on PET/MR Reconstruction Artifacts: Comparison of Free-breathing versus Breath-hold MR-based Attenuation Correction. Radiology, 2017, 282, 229-235.	7.3	16
60	The Effect of Susceptibility Artifacts Related to Metallic Implants on Adjacent-Lesion Assessment in Simultaneous TOF PET/MR. Journal of Nuclear Medicine, 2017, 58, 1167-1173.	5.0	8
61	PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. Clinical Imaging, 2017, 42, 232-239.	1.5	43
62	Comparison of Contrast-Enhanced CT and [18F]FDG PET/CT Analysis Using Kurtosis and Skewness in Patients with Primary Colorectal Cancer. Molecular Imaging and Biology, 2017, 19, 795-803.	2.6	32
63	Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT. Head and Neck, 2017, 39, 1550-1558.	2.0	35
64	EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 17-31.	6.4	206
65	Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1223-1233.	6.4	20
66	Clinical evaluation of a block sequential regularized expectation maximization reconstruction algorithm in 18F-FDG PET/CT studies. Nuclear Medicine Communications, 2017, 38, 57-66.	1.1	42
67	The Effect of Defective PET Detectors in Clinical Simultaneous [18F]FDG Time-of-Flight PET/MR Imaging. Molecular Imaging and Biology, 2017, 19, 626-635.	2.6	5
68	Optimizing a perfusion CT protocol for head and neck cancer. Current Directions in Biomedical Engineering, 2017, 3, 591-594.	0.4	1
69	Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach. Turkish Journal of Urology, 2017, 43, 152-157.	1.3	1
70	Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain ¹⁸ F-FDG PET/MRI: Comparison with Atlas Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 1927-1932.	5.0	102
71	Evaluation of Atlas-Based Attenuation Correction for Integrated PET/MR in Human Brain: Application of a Head Atlas and Comparison to True CT-Based Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 215-220.	5.0	80
72	Multi-Atlas-Based Attenuation Correction for Brain 18F-FDG PET Imaging Using a Time-of-Flight PET/MR Scanner: Comparison with Clinical Single-Atlas and CT-Based Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 1258-1264.	5.0	29

#	ARTICLE	IF	CITATIONS
73	Effect of Attenuation Correction on Regional Quantification Between PET/MR and PET/CT: A Multicenter Study Using a 3-Dimensional Brain Phantom. <i>Journal of Nuclear Medicine</i> , 2016, 57, 818-824.	5.0	11
74	Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. <i>Lung Cancer</i> , 2016, 94, 40-45.	2.0	21
75	TNM Staging of Non- ¹⁸ F-Small Cell Lung Cancer: Comparison of PET/MR and PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 21-26.	5.0	65
76	Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 400-408.	2.0	27
77	Osseous vitality in single photon emission computed tomography/computed tomography (SPECT/CT) after balloon tibioplasty of the tibial plateau: a case series. <i>BMC Medical Imaging</i> , 2015, 15, 56.	2.7	4
78	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. <i>BMC Cancer</i> , 2015, 15, 1002.	2.6	42
79	Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study. <i>BMC Medical Imaging</i> , 2015, 15, 60.	2.7	7
80	Intra-individual comparison of PET/CT with different body weight-adapted FDG dosage regimens. <i>Acta Radiologica Open</i> , 2015, 4, 204798161456007.	0.6	9
81	Workflow in Simultaneous PET/MRI. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 332-344.	4.6	32
82	Guest Editorial. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 189-191.	4.6	6
83	Pitfalls and Limitations in Simultaneous PET/MRI. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 552-559.	4.6	16
84	Clinical evaluation of PET image quality as a function of acquisition time in a new TOF-PET/MR compared to TOF-PET/CT - initial results. <i>EJNMMI Physics</i> , 2015, 2, A76.	2.7	3
85	Tumor stage, tumor site and HPV dependent correlation of perfusion CT parameters and [18F]-FDG uptake in head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015, 117, 125-131.	0.6	18
86	Hybrid PET/MR Imaging: An Algorithm to Reduce Metal Artifacts from Dental Implants in Dixon-Based Attenuation Map Generation Using a Multiacquisition Variable-Resonance Image Combination Sequence. <i>Journal of Nuclear Medicine</i> , 2015, 56, 93-97.	5.0	28
87	Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT. <i>PLoS ONE</i> , 2015, 10, e0128842.	2.5	30
88	Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. <i>Swiss Medical Weekly</i> , 2015, 145, w14116.	1.6	11
89	Clinical image quality perception and its relation to NECR measurements in PET. <i>EJNMMI Physics</i> , 2014, 1, 103.	2.7	15
90	Whole-Body Nonenhanced PET/MR versus PET/CT in the Staging and Restaging of Cancers: Preliminary Observations. <i>Radiology</i> , 2014, 273, 859-869.	7.3	78

#	ARTICLE	IF	CITATIONS
91	Metal artifact reduction in patients with dental implants using multispectral three-dimensional data acquisition for hybrid PET/MRI. EJNMMI Physics, 2014, 1, 102.	2.7	36
92	PET/MRI and PET/CT in follow-up of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1066-75.	6.4	68
93	Generation of pseudo-CT from a single MRI for PET/MR attenuation correction purposes. EJNMMI Physics, 2014, 1, A74.	2.7	2
94	Dynamic comparison of PET imaging performance between state-of-the-art ToF-PET/CT and ToF-PET/MR scanners. EJNMMI Physics, 2014, 1, A75.	2.7	1
95	Cluster-based segmentation of dual-echo ultra-short echo time images for PET/MR bone localization. EJNMMI Physics, 2014, 1, 7.	2.7	18
96	Contrast-Enhanced PET/MR Imaging Versus Contrast-Enhanced PET/CT in Head and Neck Cancer: How Much MR Information Is Needed?. Journal of Nuclear Medicine, 2014, 55, 551-558.	5.0	123
97	The clinical rehabilitation of spine and spinal cord disorders: detection and evaluation using SPECT/CT. Neural Regeneration Research, 2014, 9, 795.	3.0	5
98	Evaluation of MR acquisition strategies for MR based attenuation correction. , 2013, , .		0
99	Combined PET/CT-perfusion in patients with head and neck cancers. European Radiology, 2013, 23, 163-173.	4.5	18
100	Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. European Radiology, 2011, 21, 256-264.	4.5	8